Cargando…

Anticoagulation during continuous renal replacement therapy with lepirudin in patients with heparin-induced thrombocytopenia

Detalles Bibliográficos
Autores principales:	Schroeder, T, Karcher, C, Engelmann, G, Krueger, W, Unertl, K
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2005
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4098500/ http://dx.doi.org/10.1186/cc3413

Ejemplares similares

Lepirudin in the management of patients with heparin-induced thrombocytopenia
por: Petros, Sirak
Publicado: (2008)

Comparison between nafamostat mesilate and unfractionated heparin as anticoagulant during continuous renal replacement therapy
por: Makino, S, et al.
Publicado: (2015)

Extracorporeal renal replacement therapy in patients with heparin-induced thrombocytopenia
por: Bekers-Anchipolovskis, M, et al.
Publicado: (2009)

Lepirudin as an alternative to "heparin allergy" during cardiopulmonary bypass
por: Parissis, Haralabos
Publicado: (2011)

Bilateral Renal Artery Thrombosis due to Heparin-Induced Thrombocytopenia-Thrombosis Syndrome. Successful treatment with longterm application of lepirudin
por: Tsirigotis, Panagiotis, et al.
Publicado: (2006)

Use of activated clotting time to monitor anticoagulation in patients receiving unfractionated heparin on renal replacement therapy
por: Bidwai, A, et al.
Publicado: (2011)

Heparin algorithm for anticoagulation during continuous renal replacement therapy
por: Ostermann, Marlies, et al.
Publicado: (2010)

Revised algorithm for heparin anticoagulation during continuous renal replacement therapy
por: Dickie, Helen, et al.
Publicado: (2015)

Heparin vs recombinant hirudin for anticoagulation in continuous renal replacement therapy
por: Vargas Hein, O, et al.
Publicado: (2000)

Clinical review: Anticoagulation for continuous renal replacement therapy - heparin or citrate?
por: Oudemans-van Straaten, Heleen M, et al.
Publicado: (2011)

Evaluation of functional differences between two anticoagulation methods used in continuous renal replacement therapy in critical patients
por: Goulão, V, et al.
Publicado: (2014)

Citrate versus heparin anticoagulation in continuous renal replacement therapy in small children
por: Raymakers-Janssen, Paulien A. M. A., et al.
Publicado: (2017)

Combined use of pumpless extracorporeal lung assist system and continuous renal replacement therapy with citrate anticoagulation in polytrauma patients
por: Atalan, HK, et al.
Publicado: (2013)

Influence of thiopentone and midazolam on monocyte differentiation into dendritic cells
por: Karcher, C, et al.
Publicado: (2005)

Protein losses in continuous renal replacement therapies
por: Rodigues, MG, et al.
Publicado: (2005)

Consequences of suspected heparin-induced thrombocytopenia in the ICU
por: Ostermann, M, et al.
Publicado: (2012)

Amino acid adherence in continuous renal replacement therapies
por: Rodrigues, MG, et al.
Publicado: (2005)

Orgaran(® )use in intensive care unit patients with heparin-induced thrombocytopenia and acute renal failure
por: Magnani, H, et al.
Publicado: (2007)

Protein losses and nitrogen balance during continuous renal replacement therapy
por: Hayami, H, et al.
Publicado: (2011)

Metabolic disturbances encountered during pediatric continuous renal replacement therapy
por: Soysal, D, et al.
Publicado: (2006)

Association between type of anticoagulation and blood transfusion requirements during renal replacement therapy in the ICU
por: Iyer, A, et al.
Publicado: (2011)

Heparin-induced thrombocytopenia incidence in the ICU: preliminary results
por: Barbani, F, et al.
Publicado: (2010)

Blood epuration of middle molecules in continuous venovenous hemodiafiltration with regional citrate anticoagulation versus systemic heparinization
por: Nogier, MB, et al.
Publicado: (2009)

Preventing continuous renal replacement therapies (CRRT)-induced hypophosphatemia using a phosphate-containing CRRT solution in the setting of regional citrate anticoagulation
por: Pistolesi, V, et al.
Publicado: (2014)

Continuous renal replacement therapy: are we getting the dose right?
por: Martin, S, et al.
Publicado: (2010)

Tedizolid clearance by in vitro continuous renal replacement therapy model
por: Lewis, SJ, et al.
Publicado: (2015)

Pharmacokinetics of meropenem during continuous renal replacement therapy in critically ill patients
por: Solé Violan, J, et al.
Publicado: (2014)

The beneficial effects of the combined methods in investigating heparin-induced thrombocytopenia
por: Kounavi, M, et al.
Publicado: (2007)

Effect of heparin during extracorporeal detoxification in the severity of thrombocytopenia in patients with severe sepsis
por: Kulabukhov, VV, et al.
Publicado: (2012)

Argatroban for heparin-induced thrombocytopenia therapy in ICU patients with sepsis or multiple organ dysfunction syndrome
por: Saugel, B, et al.
Publicado: (2009)

Heparin-induced thrombocytopenia during renal replacement therapy in the intensive care unit
por: Davenport, Andrew
Publicado: (2008)

Determinants of renal recovery and mortality inpatients undergoing continuous renal replacement therapy in the ICU
por: Gleeson, PJ, et al.
Publicado: (2015)

Removal of inflammatory mediators by continuous renal replacement therapy in severe sepsis
por: Tomas, E, et al.
Publicado: (2009)

Evaluation of microcirculation before and during continuous renal replacement therapy and the impact of dose prescription
por: Pipili, C, et al.
Publicado: (2012)

Recovery of renal function after acute kidney injury requiring continuous renal replacement therapy
por: Jung, HY, et al.
Publicado: (2014)

Coagulopathy of liver disease does not increase the filter life during continuous renal replacement therapy
por: Agarwal, B, et al.
Publicado: (2009)

Rotational thromboelastography in a patient with heparin-induced thrombocytopenia: a case report
por: Silva, EA, et al.
Publicado: (2007)

Safety of drotrecogin alfa (activated) treatment in patients with severe sepsis on renal replacement therapy without additional anticoagulation
por: Mirea, L, et al.
Publicado: (2011)

Regional citrate anticoagulation versus systemic heparin anticoagulation for continuous kidney replacement therapy in intensive care
por: Doidge, James C., et al.
Publicado: (2023)

Glutamine serum, adherence and losses in continuous renal replacement therapies in critically ill patients
por: Rodigues, MG, et al.
Publicado: (2005)

Cannot write session to /tmp/vufind_sessions/sess_f49oi3bdqo8udr0ndloknlfrbg